NewGenIvf Reports Strong Financial Performance Amid Market Gains
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Source: NASDAQ.COM
NewGenIvf Group Ltd's stock fell 13.91% as it crossed below the 5-day SMA, despite positive market conditions with the Nasdaq-100 up 1.24% and the S&P 500 up 0.70%.
The company reported a net profit of $9.9 million for FY 2025, a significant increase from the previous year, driven by strategic acquisitions including Nodexus and Microsort. Additionally, total assets surged to $32.7 million, reflecting effective capital management and business expansion. The company also initiated a $2 million share repurchase program, indicating management's confidence in its intrinsic value.
These results highlight NewGenIvf's strong market performance and strategic growth initiatives, although the stock's decline suggests a potential sector rotation despite the overall market strength.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NIVF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NIVF
About NIVF
NewGenIVF Group Limited is a diversified healthcare and technology-driven platform focused on investments across fertility services, consumer wellness, digital assets, and real estate. The Company operates through three business divisions, which include NewGenProperty, which operates real estate development projects in the United Arab Emirates (UAE)'s Ras Al Khaimah Emirate; NewGenDigital, which serves as the Company's digital asset and decentralized finance (DeFi) solutions arm, and NewGenSup, which focuses on health and longevity products and solutions. Its legacy business involves providing in-vitro fertilization (IVF) and assisted reproductive treatment services, such as surrogacy and egg freezing across Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NewGen Acquires Stake in K25.ai and Signs Exclusive Agency Agreement
- Equity Acquisition: NewGen has executed a Share Purchase Agreement to acquire a 2% equity stake in K25.ai for $2 million, implying a $100 million valuation, with the option to increase its ownership to 10%, strategically positioning NewGen in the emerging prediction market.
- Exclusive Agency Agreement: NewGen is appointed as K25.ai's exclusive agency partner for selected APAC markets, expected to create a high-margin commercial growth channel for NewGen, with an initial three-year term and renewal potential.
- Market Opportunity: According to Bernstein research, prediction market volumes are projected to reach approximately $1 trillion by 2030, up from about $51 billion in 2025, indicating significant growth potential in this sector.
- APAC Market Advantages: The digital economy, mobile-first infrastructure, and strong gaming and esports communities in the APAC region provide a compelling foundation for K25.ai's localized prediction market platform, with NewGen's investment further driving this strategic initiative.
See More
NewGenIVF Enters Strategic Investment Agreement with K25.ai
- Strategic Investment Agreement: NewGenIVF has entered into a strategic investment agreement with K25.ai, making an initial investment of $2 million at a $100 million valuation, positioning NewGenIVF within the rapidly growing AI and live-streaming market.
- Investment Option: NewGenIVF has the option to increase its investment to $10 million, which, if fully exercised, will further enhance its market influence in the Asia-Pacific region, particularly in the prediction market sector.
- Exclusive Agency Agreement: NewGenIVF will act as the exclusive agent for K25.ai in markets such as Thailand, Singapore, and Japan, with expectations to earn commissions based on gross profits from introduced customers, creating new commercial revenue streams.
- Board Nomination: K25.ai will nominate three independent director candidates, with NewGenIVF's board expected to expand from five to eight members, enhancing corporate governance and decision-making capabilities.
See More
NewGenIvf Reports $9.9 Million Net Profit for FY 2025
- Net Profit Surge: For the fiscal year ending December 31, 2025, NewGenIvf reported a net profit of $9.9 million, indicating a significant increase compared to 2024, reflecting the company's strong market performance and enhanced profitability.
- Substantial Asset Growth: As of December 31, 2025, total assets reached $32.7 million, a remarkable rise from $3.6 million in 2024, showcasing the company's success in business expansion and capital management.
- Increased Asset Value per Share: The asset value per share stood at $135.9 in 2025, demonstrating effective strategies in asset management and shareholder value creation, which bolsters investor confidence.
- Significant Acquisition Value: In July 2025, the company completed the acquisition of advanced cytometry intellectual property, independently valued at $17.9 million by a big-four accounting firm, resulting in a bargain purchase gain of $19.2 million, further solidifying the company's market position.
See More
NewGen Reports Strong Financial Performance
- Significant Asset Growth: As of December 31, 2025, NewGen's total assets reached $32.7 million, a substantial increase from $3.6 million in 2024, demonstrating a marked improvement in financial stability that enhances investor confidence.
- Strong Net Profit Performance: In 2025, NewGen reported a net profit attributable to shareholders of $9.9 million, primarily driven by a bargain purchase gain from the acquisition of Nodexus and Microsort, indicating successful strategic acquisitions that boosted profitability.
- Share Repurchase Program: The company authorized a $2 million share repurchase program in November 2025, reflecting management's confidence in the company's intrinsic value and aiming to enhance shareholder returns by reducing the number of outstanding shares.
- Advancement of Diversification Strategy: NewGen continues to push forward its diversification strategy in digital asset innovation and health supplements, indicating the company's commitment to seizing emerging opportunities in rapidly evolving markets for long-term growth and sustainability.
See More
NewGenIVF Partners with WiW3 to Enhance Women's Health Awareness
- MOU Signing: NewGenIVF has signed a Memorandum of Understanding with Women in Web3 Hong Kong to collaborate on a public awareness and education campaign focused on women's health literacy, aiming to improve family planning and legacy design.
- Diverse Activities: The campaign will feature talks, panel discussions, and community events that emphasize women's health, financial inclusion, and responsible use of emerging technologies, aiming to empower women through knowledge and open dialogue.
- Integrated Technical Support: NewGen will leverage expertise from its health and longevity products division to provide comprehensive, technology-enabled educational resources that help women make informed choices in their health journeys.
- Aligned Strategic Goals: This partnership aligns with NewGen's broader mission to advance women's health through its diversified subsidiaries, ensuring women are not just users but shapers of emerging technologies, enhancing their agency in life design.
See More
NewGenIVF Group's Remarkable Financial Transformation
- Financial Improvement: As of September 30, 2025, NewGenIVF Group successfully transformed a historical deficit into $28 million in net assets, demonstrating the effectiveness of its capital management strategy and laying a solid foundation for future growth.
- Diversification Strategy: In 2025, the company acquired advanced cytometry intellectual property valued at $17.9 million, forming the cornerstone of a new technology-licensing business expected to drive high-margin revenue streams and enhance market competitiveness.
- Digital Asset Innovation: The NewGenDigital division is pioneering Real World Asset tokenization and plans to launch its first proprietary digital token in 2026, which will open new capital sources to support business development.
- Share Repurchase Program: In November 2025, the company authorized a $2 million share repurchase program, reflecting management's confidence in the company's intrinsic value and aiming to enhance shareholder value, marking a transition into a harvesting phase.
See More
NewGen Acquires Stake in K25.ai and Signs Exclusive Agency Agreement
- Equity Acquisition: NewGen has executed a Share Purchase Agreement to acquire a 2% equity stake in K25.ai for $2 million, implying a $100 million valuation, with the option to increase its ownership to 10%, strategically positioning NewGen in the emerging prediction market.
- Exclusive Agency Agreement: NewGen is appointed as K25.ai's exclusive agency partner for selected APAC markets, expected to create a high-margin commercial growth channel for NewGen, with an initial three-year term and renewal potential.
- Market Opportunity: According to Bernstein research, prediction market volumes are projected to reach approximately $1 trillion by 2030, up from about $51 billion in 2025, indicating significant growth potential in this sector.
- APAC Market Advantages: The digital economy, mobile-first infrastructure, and strong gaming and esports communities in the APAC region provide a compelling foundation for K25.ai's localized prediction market platform, with NewGen's investment further driving this strategic initiative.
See More
NewGenIVF Enters Strategic Investment Agreement with K25.ai
- Strategic Investment Agreement: NewGenIVF has entered into a strategic investment agreement with K25.ai, making an initial investment of $2 million at a $100 million valuation, positioning NewGenIVF within the rapidly growing AI and live-streaming market.
- Investment Option: NewGenIVF has the option to increase its investment to $10 million, which, if fully exercised, will further enhance its market influence in the Asia-Pacific region, particularly in the prediction market sector.
- Exclusive Agency Agreement: NewGenIVF will act as the exclusive agent for K25.ai in markets such as Thailand, Singapore, and Japan, with expectations to earn commissions based on gross profits from introduced customers, creating new commercial revenue streams.
- Board Nomination: K25.ai will nominate three independent director candidates, with NewGenIVF's board expected to expand from five to eight members, enhancing corporate governance and decision-making capabilities.
See More
NewGenIvf Reports $9.9 Million Net Profit for FY 2025
- Net Profit Surge: For the fiscal year ending December 31, 2025, NewGenIvf reported a net profit of $9.9 million, indicating a significant increase compared to 2024, reflecting the company's strong market performance and enhanced profitability.
- Substantial Asset Growth: As of December 31, 2025, total assets reached $32.7 million, a remarkable rise from $3.6 million in 2024, showcasing the company's success in business expansion and capital management.
- Increased Asset Value per Share: The asset value per share stood at $135.9 in 2025, demonstrating effective strategies in asset management and shareholder value creation, which bolsters investor confidence.
- Significant Acquisition Value: In July 2025, the company completed the acquisition of advanced cytometry intellectual property, independently valued at $17.9 million by a big-four accounting firm, resulting in a bargain purchase gain of $19.2 million, further solidifying the company's market position.
See More
NewGen Reports Strong Financial Performance
- Significant Asset Growth: As of December 31, 2025, NewGen's total assets reached $32.7 million, a substantial increase from $3.6 million in 2024, demonstrating a marked improvement in financial stability that enhances investor confidence.
- Strong Net Profit Performance: In 2025, NewGen reported a net profit attributable to shareholders of $9.9 million, primarily driven by a bargain purchase gain from the acquisition of Nodexus and Microsort, indicating successful strategic acquisitions that boosted profitability.
- Share Repurchase Program: The company authorized a $2 million share repurchase program in November 2025, reflecting management's confidence in the company's intrinsic value and aiming to enhance shareholder returns by reducing the number of outstanding shares.
- Advancement of Diversification Strategy: NewGen continues to push forward its diversification strategy in digital asset innovation and health supplements, indicating the company's commitment to seizing emerging opportunities in rapidly evolving markets for long-term growth and sustainability.
See More
NewGenIVF Partners with WiW3 to Enhance Women's Health Awareness
- MOU Signing: NewGenIVF has signed a Memorandum of Understanding with Women in Web3 Hong Kong to collaborate on a public awareness and education campaign focused on women's health literacy, aiming to improve family planning and legacy design.
- Diverse Activities: The campaign will feature talks, panel discussions, and community events that emphasize women's health, financial inclusion, and responsible use of emerging technologies, aiming to empower women through knowledge and open dialogue.
- Integrated Technical Support: NewGen will leverage expertise from its health and longevity products division to provide comprehensive, technology-enabled educational resources that help women make informed choices in their health journeys.
- Aligned Strategic Goals: This partnership aligns with NewGen's broader mission to advance women's health through its diversified subsidiaries, ensuring women are not just users but shapers of emerging technologies, enhancing their agency in life design.
See More
NewGenIVF Group's Remarkable Financial Transformation
- Financial Improvement: As of September 30, 2025, NewGenIVF Group successfully transformed a historical deficit into $28 million in net assets, demonstrating the effectiveness of its capital management strategy and laying a solid foundation for future growth.
- Diversification Strategy: In 2025, the company acquired advanced cytometry intellectual property valued at $17.9 million, forming the cornerstone of a new technology-licensing business expected to drive high-margin revenue streams and enhance market competitiveness.
- Digital Asset Innovation: The NewGenDigital division is pioneering Real World Asset tokenization and plans to launch its first proprietary digital token in 2026, which will open new capital sources to support business development.
- Share Repurchase Program: In November 2025, the company authorized a $2 million share repurchase program, reflecting management's confidence in the company's intrinsic value and aiming to enhance shareholder value, marking a transition into a harvesting phase.
See More
